

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5583623

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CHARLES GLASS	11/07/2018
BRYAN THACKER	11/07/2018
JEFFREY ESKO	11/07/2018
RECEIVING PARTY DATA	
Name:	TEGA THERAPEUTICS, INC.
Street Address:	3550 GENERAL ATOMICS COURT
Internal Address:	G02-102
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16063670
CORRESPONDENCE DATA	
Fax Number:	(858)350-2399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8583502300
Email:	patentdocket@wsgr.com,hglasson@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	45399-703.831
NAME OF SUBMITTER:	HEATHER GLASSON
SIGNATURE:	/Heather Glasson/
DATE SIGNED:	06/20/2019
Total Attachments: 3	
source=45399-703.831 Assignment_executed#page1.tif	
source=45399-703.831 Assignment_executed#page2.tif	
source=45399-703.831 Assignment_executed#page3.tif	

WHEREAS, the undersigned:

- | | | |
|--|---|--|
| 1. Charles GLASS
9500 Gilman Drive, MC 0713
La Jolla, CA 92093 | 2. Bryan THACKER
9500 Gilman Drive
La Jolla, CA 92093 | 3. Jeffrey ESKO
9500 Gilman Drive
La Jolla, CA 92093 |
|--|---|--|

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING

☒ for which application serial number 16/063,670, a U.S. National Phase of PCT/US16/67373 filed on December 16, 2016 in the Receiving Office of the Patent Cooperation Treaty, was filed on June 18, 2018 in the United States Patent and Trademark Office;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, TEGA Therapeutics, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 9500 Gilman Drive, MC 0713, La Jolla, CA 92093-0713, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 11/7/18 Charles C. Glass
Charles Glass

Witness: CLM
Colin M. Cartwright
(printed name)

Date: 11/7/18

Address: 4290 Mt Abernathy AVE
San Diego CA 92117

Witness: JMR
JILLIAN R. BROWN
(printed name)

Date: 7 NOV 2018

Address: 13655 Ash Hollow
Pomona, CA, 92064

Date: 11/7/18 Bryan
Bryan THACKER

Witness: CLM
Colin M. Cartwright
(printed name)

Date: 11/7/18

Address: 4290 Mt Abernathy AVE
San Diego CA 92117

Witness: JMR
JILLIAN R. BROWN
(printed name)

Date: 7 NOV 2018

Address: 13655 Ash Hollow
Pomona, CA, 92064

PATENT ASSIGNMENT

Docket Number 45399-703.831

Date: 11/7/18

Jeffrey ASKO

Witness:

JILLIAN BROWN

(printed name)

Date: 7, Nov, 2018

Address:

13655 ASH HOLLOW
POWAY, CA 92064

Witness:

Colin M. Cortwright

(printed name)

Date: 11/7/18

Address:

4290 Mt Abernathy AVE
San Diego CA 92117

RECEIVED AND AGREED TO BY ASSIGNEE:

TEGA THERAPEUTICS, INC.

Date: 11/7/2018

Signature:

Name: Charles Glass

Title: President & CSO